Introducing Aurora Licaj DC3

My PhD goals: Research project DC3 aims to develop a scalable and cGMP compatible process to generate kidney organoids and tubuloids, using 3D cell culture approaches and stirred-tank bioreactor technology.

My Background: After completing my bachelor’s degree in Medical Biotechnology at the University of Padua, Italy, I moved to Belgium to pursue a master’s degree in Biochemistry and Biotechnology at KU Leuven. During this time, I conducted my thesis research on cystic fibrosis in the group of Dr. Marianne S. Carlon, where I was introduced to primary cell cultures and intestinal organoids. Additionally, I participated in the International Genetically Engineered Machine (iGEM) competition as part of my university team, which allowed me to work in the field of synthetic biology while further developing my teamwork skills and deepening my passion for research.

My research interests: I have always been interested in human pathologies, particularly rare diseases. During my master’s thesis, I became fascinated by the remarkable potential of organoids to advance research in this area. Additionally, my studies in biotechnology have sparked a strong interest in applying this knowledge to bridge the gap between academic research and industrial applications.

My hobbies: I have many hobbies and I often take up new ones based on my current interests. I usually enjoy reading, playing the piano and guitar, going to the gym, exploring photography and art, experimenting with cooking and hiking with my friends.

Master thesis: Design and validation of reporters to unravel CFTR function in different airway epithelial cell types

Cystic fibrosis (CF) is a common genetic disease caused by mutations in the CFTR gene, leading to defective cystic fibrosis transmembrane conductance regulator (CFTR) protein function. This results in thick mucus buildup, primarily affecting the lungs and digestive system, causing respiratory issues, infections, and complications in organs like the pancreas. With over 2,000 known CFTR mutations, the severity of symptoms varies widely. Current treatments, including mucus-thinning drugs, antibiotics, and CFTR modulators, focus on symptom management but are not curative. A key challenge in developing a cure is understanding how CFTR functions in different airway cell types, as these cells play unique roles in lung health. This thesis work aimed to create specialized tools called “reporters”, designed to be expressed only in the cells of interest and linked to a fluorescent protein that lights up when CFTR is active. Validated in simple and complex models, these reporters allow precise measurement of CFTR function in different cell types, advancing our understanding of the disease and paving the way for personalised therapies and potential cures.